Reported 2 days ago
AbCellera Biologics Inc. (NASDAQ:ABCL), a company focused on developing therapeutic antibodies, has started a Phase 1 clinical trial for ABCL635, aimed at alleviating menopause-related vasomotor symptoms. This marks a significant step as the company transitions from a discovery platform to a clinical-stage biotech firm. Despite ongoing net losses, AbCellera reported strong revenue growth in Q2 2025, indicating the potential of its innovative pipeline in the biotech sector.
Source: YAHOO